A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetic Profile of JNJ-56021927 When Administered as the Tablet Formulation in Healthy Male Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2017
At a glance
- Drugs Apalutamide (Primary)
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors Janssen Pharmaceutical KK
- 10 Jan 2017 Status changed from active, no longer recruiting to completed.
- 18 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 22 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.